Yonit Marcus, Ph.D. - Publications
Affiliations: | 2010 | Weizmann Institute of Science, Rehovot, Israel |
Area:
Histology Biology, Physiology BiologyYear | Citation | Score | |||
---|---|---|---|---|---|
2013 | Marcus Y, Shefer G, Sasson K, Kohen F, Limor R, Pappo O, Nevo N, Biton I, Bach M, Berkutzki T, Fridkin M, Benayahu D, Shechter Y, Stern N. Angiotensin 1-7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model. Diabetes. 62: 1121-30. PMID 23250359 DOI: 10.2337/Db12-0792 | 0.503 | |||
2012 | Shechter Y, Sasson K, Marcus Y, Rubinraut S, Lev-Goldman V, Fridkin M. Establishing the principle of reversibility in peptide/protein and small-molecule therapy. Therapeutic Delivery. 3: 17-23. PMID 22833930 DOI: 10.4155/Tde.11.133 | 0.504 | |||
2010 | Sasson K, Marcus Y, Lev-Goldman V, Rubinraut S, Fridkin M, Shechter Y. Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions. Journal of Controlled Release : Official Journal of the Controlled Release Society. 142: 214-20. PMID 19883707 DOI: 10.1016/J.Jconrel.2009.10.028 | 0.524 | |||
2008 | Marcus Y, Sasson K, Fridkin M, Shechter Y. Turning low-molecular-weight drugs into prolonged acting prodrugs by reversible pegylation: a study with gentamicin. Journal of Medicinal Chemistry. 51: 4300-5. PMID 18578475 DOI: 10.1021/Jm8002558 | 0.511 | |||
2008 | Shechter Y, Mironchik M, Rubinraut S, Tsubery H, Sasson K, Marcus Y, Fridkin M. Reversible pegylation of insulin facilitates its prolonged action in vivo. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft FüR Pharmazeutische Verfahrenstechnik E.V. 70: 19-28. PMID 18495444 DOI: 10.1016/J.Ejpb.2008.03.018 | 0.523 | |||
Show low-probability matches. |